Metastatic Pattern in Non-resectable Non-small Cell Lung Cancer

References

• Naruke T, Goya T, Tsuchiya R, Suemasu K. Prognosis and survival in resected lung carcinoma based on the new interna-tional staging system. J Thorac Cardiovasc Surg 1988; 96: 440–7.
   PubMed Web of Science ®Google Scholar
• Hansen HH. Advanced non-small cell lung cancer. To treat or not treat? J Clin Oncol 1987; 5: 1711–2.
   PubMedGoogle Scholar
• Sorensen JB, Badsberg JH, Hansen HH. Response to cyto-static treatment in inoperable adenocarcinoma of the lung. Critical implications. Br J Cancer 1989; 60: 389–93.
   PubMedGoogle Scholar
• Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small-cell lung cancer: a meta analysis. Lancet 1993; 342: 19–21.
   PubMed Web of Science ®Google Scholar
• Elliot JA, Osterlind K, Hirsch FR, Hansen HH. Metastatic pattern in small-cell lung cancer: correlation of autopsy find-ings with clinical parameters in 537 patients. J Clin Oncol 1987; 5: 246–54.
   PubMedGoogle Scholar
• Stenbygaard LE, Sorensen JB, Olsen JE. Metastatic pattern in adenocarcinoma of the lung. J Thorac Cardiovasc Surg 1995; 110: 1130–5.
   PubMedGoogle Scholar
• Stenbygaard LE, Sorensen JB, Olsen JE. Metastatic pattern at autopsy in non-resectable adenocarcinoma of the lung. Acta Oncol 1997; 36: 301–6.
   Google Scholar
• Sorensen JB, Badsberg JH, Olsen JE. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients. Cancer Res 1989; 49: 5748–54.
   Google Scholar
• Storm HH, Andersen J. Percentage of autopsies in cancer patients in Denmark in 1971-1980 (Danish). Ugeskr Lwger 1986; 148: 1110–4.
   PubMedGoogle Scholar
• Roberts WC. The autopsy: its decline and a suggestion for its revival. N Engl J Med 1978; 299: 332–8.
   PubMedGoogle Scholar
• Geller SA. Autopsy. Sci Am 1983; 2: 124–36.
   Google Scholar
• Szende B, Kendrey G, Lapis K, Roe FJ, Lee PN. Accuracy of admission and clinical diagnosis of tumours as revealed by 2000 autopsies. Eur J Cancer 1996; 32A (7): 1102–8.
   Google Scholar
• Editorial. Research after death. Lancet 1994; 344: 1517–8.
   PubMedGoogle Scholar
• Lee PN. Comparison of autopsy, clinical, and death certificate diagnosis with particular reference to lung cancer. A review of published data. APMIS 1994; (Suppl 45): 1–42.
   Google Scholar
• Larsen H, Sorensen JB, Nielsen AL, Dombernowsky P, Hansen HH. Evaluation of the optimal duration of chemotherapy in phase II trials for inoperable non-small-cell lung cancer (NSCLC). Ann of Oncol 1995; 6: 993–7.
   Google Scholar
• Vibe-Petersen J, Bach F, Pedersen AG, et al. A phase II trial of TCNU in patients with squamous, adeno and large-cell carcinoma of the lung. Eur J Cancer Clin Oncol 1990; 25: 1881–25.
   Google Scholar
• Sorensen JB, Hansen HH, Dombernowsky P, et al. Chemotherapy for adenocarcinoma of the lung (WHO 3): a randomized study of vindesine versus lomustine, cyclophos-phamide and methotrexate versus all four drugs. J Clin Oncol 1987; 5: 1169–77.
   PubMedGoogle Scholar
• Bach F, Vibe-Petersen J, Sorensen JB, et al. Phase II trial of TCNU and vindesine in patients with adenocarcinoma of the lung. Eur J Cancer 1990; 26: 545.
   PubMedGoogle Scholar
• Sorensen JB, Stenbygaard L, Drivsholm L, et al. Phase II study of 4-iodo-deoxydoxorubicin in nonresectable non-small cell lung cancer. Cancer Chemother Pharmacol 1993; 32: 399–402.
   PubMedGoogle Scholar
• Anderson H, Lund B, Bach F, et al. Single agent activity of weekly gemcitabine in advanced non-small cell lung cancer. A phase II study. J Clin Oncol 1994; 12: 1821–6.
   PubMed Web of Science ®Google Scholar
• Lund B, Ryberg M, Meidal Petersen P, et al. Phase II study of gemcitabine (2,2-difluorodeoxycytidine) given as twice-weekly schedule to previously untreated patients with non-small cell lung cancer. Ann Oncol 1994; 5: 852–3.
   PubMedGoogle Scholar
• Sorensen JB, Bach F, Dombernowsky P, Hansen HH. Phase II study of teniposide in adenocarcinoma of the lung. Cancer Chemother Pharmacol 1991; 27: 487–9.
   PubMedGoogle Scholar
• Sorensen JB, Nielsen AL, Krarup M, et al. Phase II study of gemcitabine vindesine in patients with previously untreated inoperable non-small cell lung cancer (NSCLC). Lung Cancer 1994; 11 (Suppl 1) P: 116.
   Google Scholar
• Mountain CF. The new international system for staging of lung cancer. Chest 1986; 89 (Suppl): 225S–33S.
   Google Scholar
• World Health Organization. Histological typing of lung tu-mors, 2nd ed. WHO, Geneva, 1981: 1–41.
   Google Scholar
• WHO: Handbook for reporting results of cancer treatment. Geneva, World Health Organization, 1979.
   Google Scholar
• Fushimi H, Kikui M, Morino H, et al. Histologic changes in small cell lung carcinoma after treatment. Cancer 1996; 77: 278–83.
   PubMedGoogle Scholar
• Matthews MJ, Kanhouwa S, Pickren J, Robinette D. Fre-quency of residual and metastatic tumor in patients undergo-ing curative surgical resection for lung cancer. Cancer Chemother Rep 1973; 3: 63–7.
   Google Scholar
• Martini N, Burt ME, Bains MS, McCormack PM, Rusch VW, Ginsberg RJ. Survival after resection of stage II non-small cell lung cancer. Ann Thorac Surg 1992; 54: 460–6.
   PubMedGoogle Scholar
• Yesner R, Carter D. Pathology of carcinoma of the lung. Changing patterns. Clin Chest Med 1982; 2: 257–89.
   Google Scholar
• Onuigbo WIB. Some pathological data on 2000 adenocar-cinomas and squamous cell carcinomas of the lung. Br J Cancer 1963; 17: 1–7.
   PubMedGoogle Scholar
• Feld R, Rubinstein LV, Weisenberger TH, and the Lung Cancer Study Group. Sites of recurrence in resected stage I non-small-cell lung cancer: a guide for future studies. J Clin Oncol 1984; 12: 1352–8.
   Google Scholar
• Pairolero PC, Williams DE, Bergstrahl EJ, Piehler JM, Bemat PE. Postsurgical stage I bronchogenic carcinoma: morbid implications of recurrent disease. Ann Thorac Surg 1984; 38: 331 —8.
   Google Scholar
• Immermann SC, Vanecko RM, Fry WA, Head LR, Shields TW. Site of recurrence in patients with stages I and II carcinoma of the lung resected for cure. Ann Thorac Surg 1981; 32: 23–7.
   Google Scholar